anti-inflammatoty and immuno-therapy - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.91 [0.86, 0.96]< 120%69 studies (69/-)100.0 %some concerncritical moderatecrucial-
death or transfer to ICU 0.79 [0.50, 1.24]< 10%2 studies (2/-)84.9 %some concernnot evaluable moderatecrucial-
deaths 0.89 [0.85, 0.93]< 120%114 studies (114/-)100.0 %some concerncritical moderatecrucial1
deaths (time to event analysis only) 0.84 [0.72, 0.98]< 131%20 studies (20/-)98.8 %some concernlow moderatecrucial-
clinical deterioration 0.70 [0.57, 0.86]< 148%26 studies (26/-)100.0 %some concernlow moderateimportant-
clinical improvement 1.17 [1.08, 1.27]> 137%34 studies (34/-)100.0 %some concerncritical moderateimportant-
clinical improvement (14-day) 1.40 [1.12, 1.74]> 145%11 studies (11/-)99.9 %lowcritical highimportant-
clinical improvement (21-day) 1.50 [0.22, 10.08]> 10%1 study (1/-)66.1 %NAnot evaluable important-
clinical improvement (28-day) 1.59 [1.14, 2.21]> 148%12 studies (12/-)99.7 %some concerncritical moderateimportant-
clinical improvement (7-day) 1.32 [0.90, 1.96]> 147%7 studies (7/-)92.0 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.14 [1.04, 1.25]> 122%18 studies (18/-)99.8 %some concerncritical moderateimportant-
death or ventilation 0.90 [0.86, 0.96]< 152%27 studies (27/-)100.0 %some concerncritical moderateimportant-
hospital discharge 1.06 [1.00, 1.13]> 157%14 studies (14/-)97.1 %some concernlow moderateimportant-
hospitalization 1.00 [0.14, 7.34]< 10%1 study (1/-)50.0 %NAnot evaluable important-
mechanical ventilation 0.86 [0.78, 0.95]< 122%34 studies (34/-)99.9 %some concerncritical moderateimportant1
mechanical ventilation (time to event analysis only) 0.97 [0.62, 1.52]< 10%2 studies (2/-)55.5 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 3.18 [1.91, 5.29]> 10%4 studies (4/-)100.0 %some concernnot evaluable moderateimportant-
viral clearance 2.53 [1.31, 4.90]> 180%10 studies (10/-)99.7 %some concernlow moderateimportant-
viral clearance (time to event analysis only) 1.33 [0.77, 2.30]> 177%3 studies (3/-)84.9 %some concernnot evaluable moderateimportant-
viral clearance by day 14 1.15 [0.15, 9.03]> 197%6 studies (6/-)55.3 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.75 [1.04, 2.96]> 163%7 studies (7/-)98.2 %some concernserious moderateimportant-
ICU admission 0.76 [0.60, 0.96]< 10%13 studies (13/-)98.9 %some concernlow moderatenon important-
recovery 1.17 [0.98, 1.39]> 125%7 studies (7/-)96.2 %lownot evaluable highnon important-

safety endpoints 00

composite safety outcome 1.56 [0.78, 3.11]< 10%1 study (1/-)10.3 %NAnot evaluable important-
related AE (TRAE) 1.26 [0.14, 11.07]< 10%2 studies (2/-)41.9 %some concernnot evaluable moderateimportant-
related SAE (TRSAE) 2.04 [0.07, 63.93]< 10%1 study (1/-)34.4 %NAnot evaluable important-
serious adverse events 1.03 [0.89, 1.20]< 123%26 studies (26/-)33.8 %some concernlow moderateimportant-
superinfection 0.70 [0.46, 1.07]< 153%4 studies (4/-)95.0 %lownot evaluable highimportant-
adverse events 1.26 [1.04, 1.51]< 120%22 studies (22/-)0.9 %some concernlow moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.